Sodium‐glucose co‐transporter type‐2 inhibitors: pharmacology and peri‐operative considerations
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Summary: Sodium‐glucose co‐transporter 2 ( SGLT 2) inhibitors are an emerging class of oral hypoglycaemic agents with therapeutic benefits beyond better glycaemic control. A major concern of the sodium‐glucose co‐transporter 2 inhibitors is their propensity to cause euglycaemic ketoacidosis in the peri‐operative period and the potential for this critical diagnosis to be delayed or missed entirely. This review attempts to collate the case reports of sodium‐glucose co‐transporter 2 inhibitor ketoacidosis associated with surgery to highlight and put a perspective on this peri‐operative issue. Preventive strategies and the management of the ketoacidosis are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134 · cited 1×
“and this results in increased lipolysis and fatty acid oxidation in the liver as well as hepatic ketogenesis [7, 34].”
BackgroundPeters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837 · cited 1×
“As a consequence of decreased sodium re-absorption and the osmotic diuretic effects of glucose in the renal tubules, SGLT2 inhibitors cause a 5%–10% reduction in extracellular volume [9].”
BackgroundBonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670 · cited 1×
“In addition, alpha cells in the Islets of Langerhans express SGLT2 receptors which function as a glucose sensor [35], and are blocked by the SGLT2 inhibitors.”
BackgroundRosenstock, J., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-1380 · Cited by 664 · cited 3×
“day of glucose (approximately 30% of daily carbohydrate intake) is lost in the urine with complete SGLT2 inhibition [7].”
BackgroundHandelsman, Y., Henry, R. R., Bloomgarden, Z. T., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Ferrannini, E., Fonseca, V. A., Garber, A. J., Grunberger, G., et al. (2016) · Endocrine Practice · doi:10.4158/ep161292.ps · Cited by 358 · cited 6×
“For emergency surgical cases, SGLT2 inhibitors should be stopped immediately [21].”
BackgroundInfluentialGoldenberg, R. M., Berard, L. D., Cheng, A. Y. Y., Gilbert, J. D., Verma, S., Woo, V. C., & Yale, J.-F. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.11.002 · Cited by 354 · cited 3×
“Ideally, they should not be recommenced until the patient is clinically well, euvolaemic and tolerating a normal diet [20].”
BackgroundRisk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor
Fralick, M., Schneeweiss, S., & Patorno, E. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1701990 · Cited by 334 · cited 1×
“calculated the hazard ratios of developing diabetic ketoacidosis in patients prescribed SGLT2 inhibitors compared with dipeptidyl peptidase-4 inhibitors (DPP4) (50,220 patients were prescribed an SGLT2 inhibitor) [27].”
BackgroundKetoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data
Blau, J. E., Tella, S. H., Taylor, S. I., & Rother, K. I. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2924 · Cited by 271
SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System
Fadini, G. P., Bonora, B. M., & Avogaro, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4301-8 · Cited by 242
Cited by
Thompson, A., Fleischmann, K. E., Smilowitz, N. R., de las Fuentes, L., Mukherjee, D., Aggarwal, N. R., Ahmad, F. S., Allen, R. B., Altin, S. E., Auerbach, A., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001285 · Cited by 365
Klein, A. A., Meek, T., Allcock, E., Cook, T. M., Mincher, N., Morris, C., Nimmo, A. F., Pandit, J. J., Pawa, A., Rodney, G., et al. (2021) · Anaesthesia · doi:10.1111/anae.15501 · Cited by 340
Bamgboye, A. O., Oni, I. O., & Collier, A. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-03051-3 · Cited by 48
The peri‐operative implications of sodium‐glucose co‐transporter 2 inhibitors: a narrative review
Stewart, P. A., Nestor, C. C., Clancy, C., & Irwin, M. G. (2025) · Anaesthesia · doi:10.1111/anae.16461 · Cited by 16
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1624-3449 · Cited by 12
Metadata
- Authors
- Milder, D. A., Milder, T. Y., & Kam, P. C. A.
- Venue
- Anaesthesia
- Publisher
- Wiley
- Published
- 2018-03-12
- Volume
- 73
- Issue
- 8
- Pages
- 1008-1018
- ISSN
- 0003-2409 (ISSN-L)
- 1365-2044
- OpenAlex
- W2790875054
- Cited by
- 91
- References
- 14
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.